J&J Said to Narrow Bidder List to 3 for Diagnostics Business

Johnson & Johnson (JNJ) narrowed the list of possible buyers of its Ortho Clinical Diagnostics business to three, including a joint bid from Danaher Corp. (DHR) and Blackstone Group LP (BX), people with knowledge of the matter said.

The suitors now include Danaher-Blackstone, Carlyle Group LP and a joint offer from CVC Capital Partners Ltd. and Leonard Green & Partners LP, said the people, who asked not to be named because the process is private. J&J received interest from at least five potential bidders, mostly private-equity firms, the people said. The company hopes to have a deal done before the end of the year, one person said.

The health-care giant is trying to shed the unit because it isn’t a market leader and the company prefers to focus on molecular diagnostics, J&J Chief Executive Officer Alex Gorsky said in January. Ortho makes diagnostic equipment and sells tests for everything from cholesterol to fertility hormones. The division may fetch close to $4 billion, according to one of the people familiar with the situation.

Ernie Knewitz, a spokesman for New Brunswick, New Jersey-based J&J, declined to comment. Representatives for Blackstone, Carlyle and CVC declined to comment. A message left with Danaher outside regular business hours wasn’t returned, and a representative for Leonard Green didn’t respond to an e-mail seeking comment.

While Bain Capital Partners LLC had expressed interest in the company, it’s no longer in the running, one of the people said. A representative for Bain declined to comment.

J&J hired JPMorgan Chase & Co. to find a buyer for the diagnostic unit, according to the people familiar with the situation, after CEO Gorsky said the company would explore options for the business.

J&J rose less than 1 percent to $95.20 yesterday in New York. The shares have gained 36 percent this year.

Reuters previously reported that J&J is in final talks with two bidders, the Danaher-Blackstone group and Carlyle.

To contact the reporters on this story: Jodi Xu in New York at jxu205@bloomberg.net; David Welch in New York at dwelch12@bloomberg.net

To contact the editor responsible for this story: Jeffrey McCracken at jmccracken3@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.